Last reviewed · How we verify
Icotinib plus WBRT
Icotinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling in cancer cells, combined with whole-brain radiotherapy (WBRT) to treat brain metastases.
Icotinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling in cancer cells, combined with whole-brain radiotherapy (WBRT) to treat brain metastases. Used for Non-small cell lung cancer with EGFR mutations and brain metastases (in combination with whole-brain radiotherapy).
At a glance
| Generic name | Icotinib plus WBRT |
|---|---|
| Also known as | Commana, BPI-2009 |
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Drug class | EGFR tyrosine kinase inhibitor |
| Target | EGFR (epidermal growth factor receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Icotinib selectively inhibits EGFR tyrosine kinase activity, preventing downstream proliferation signals in EGFR-mutant lung cancer cells. When combined with WBRT, the regimen targets both systemic disease and central nervous system metastases, with potential synergistic effects on brain tumor control. This combination approach addresses the challenge of treating patients with EGFR-mutant non-small cell lung cancer who develop brain metastases.
Approved indications
- Non-small cell lung cancer with EGFR mutations and brain metastases (in combination with whole-brain radiotherapy)
Common side effects
- Rash/dermatitis
- Diarrhea
- Nausea
- Fatigue
- Radiation-related toxicity (from WBRT component)
Key clinical trials
- A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy (PHASE3)
- Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation (PHASE2)
- EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC (PHASE3)
- Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer (PHASE3)
- Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid) (PHASE3)
- Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases (PHASE4)
- Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer (PHASE2)
- Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Icotinib plus WBRT CI brief — competitive landscape report
- Icotinib plus WBRT updates RSS · CI watch RSS
- Betta Pharmaceuticals Co., Ltd. portfolio CI